Overall, while initial studies raised concerns about an elevated risk of skin cancer associated with TNFα inhibitors, more recent and comprehensive analyses suggest that these agents, whether used as monotherapy or in combination with immunosuppressants, do not significantly increase the incidence of melanoma or NMSC in patients with IBD. The gene discussed is TNF; the disease is melanoma.